In a promising development for cardiovascular health, Eli Lilly and Company's experimental gene therapy, VERVE-102, has demonstrated significant reductions in "bad" cholesterol levels during early-stage trials. This one-time treatment targets the PCSK9 gene, offering a potential new approach to managing and preventing heart disease.
Targeting the PCSK9 Gene for Lasting Impact
Heart disease remains a leading global cause of death, with coronary artery disease affecting hundreds of millions worldwide. Current treatments often require lifelong medication. VERVE-102 is designed to permanently switch off the PCSK9 gene, which is strongly linked to high levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.
The therapy aims to mimic naturally occurring genetic variants found in individuals who have lifelong low cholesterol levels and a reduced risk of heart attacks. Sekar Kathiresan, Lilly senior vice president and co-founder of Verve Therapeutics, highlighted this genetic insight: "Twenty years ago, genetics showed us that people born with PCSK9 naturally turned off have low LDL-C for life and are remarkably protected from heart attack."
Promising Phase 1b Trial Results
The Phase 1b Heart-2 trial involved 35 participants suffering from inherited high cholesterol and premature coronary artery disease. These conditions are associated with an elevated lifetime risk of cardiovascular events, including heterozygous familial hypercholesterolaemia (HeFH), which affects approximately one in 200 to 250 people globally.
- A single infusion of VERVE-102 reduced LDL cholesterol levels by up to 62%.
- This effect was durable, lasting for up to 18 months in some patients.
- Circulating PCSK9 protein levels also saw a substantial reduction, by up to 88%.
Riyaz S. Patel, a cardiologist at Barts Health NHS Trust and professor of cardiology at University College London, commented on the findings: "These early data give us encouraging evidence that in vivo base editing of PCSK9 may offer a novel approach to achieving substantial and durable LDL-C reduction with a one-time treatment."
A New Era for Cholesterol Management?
While statins and other cholesterol-lowering medications are effective and widely used, they necessitate continuous treatment. The prospect of a one-time gene-editing therapy like VERVE-102 represents a significant shift in medical strategy, attracting considerable attention from both drugmakers and investors.
Importantly, the study reported no treatment-related serious adverse events among the participants. Eli Lilly plans to advance VERVE-102 to Phase 2 studies later this year, moving closer to potentially offering a transformative solution for millions at risk of heart disease due to high cholesterol.